Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-16
2005-08-16
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S287000, C546S094000, C546S065000
Reexamination Certificate
active
06930114
ABSTRACT:
The present invention relates to pyrrolo[2.1-a]dihydroisoquinolines which are inhibitors of phosphodiesterase 10a and can be used for combating cancer.
REFERENCES:
patent: 4694085 (1987-09-01), Losel et al.
patent: 4719216 (1988-01-01), Maryanoff
patent: 0303446 (1989-02-01), None
patent: 0007348 (1969-10-01), None
patent: 1153670 (1969-05-01), None
patent: 9855118 (1998-12-01), None
patent: 0129199 (2001-04-01), None
Strandtmann et al. J. Med. Chem. (1967), 10(6);1063-1065.
Sofina et al. Experimental Evaluation of Antitumor Drugs in the USA and USSR and Clinical Correlations. NCI Monograph 55. NIH Publication No. 80-1933 (1980).
Fujishige et al. 1999, J. Biol. Chem. 274(26): 18433-18445.
Anderson, et al., “Synthesis and Antileukemic Activity of Bis[[(carbamoyl)oxy]methyl]-substituted Pyrrolo[2,1-a]isoquinolines, Pyrrolo[1,2-a]quinolines, Pyrrolo[2,1-a]isobenzazepines, and Pyrrolo[1,2-a]benzazepines”, J. Med. Chem., 31(11):2097-2102 (1988).
Meyer, H., “Pyrrolo durch cyclisierende Michael-Addition von Enaminen”, Liebigs Ann. Chem., pp. 1534-1544(1981).
Ambros, et al., “Synthesis and Antitumor Activity of Methoxy-indolo[2,1-a]isoquinolines”, Arch. Pharm., 321: 481-486(1988).
Fujishige, et al., “Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)”, J. Biol. Chem., 274(26): 18438-18445(1999).
Lowe, et al., “Growth Factor-Induced Transcription Via The Serum Response Element Is Inhibited by Cyclic Adenosine 3′,5′-Monophosphate in MCF-7 Breast Cancer Cells”, Endocrinology, 138(6): 2219-2226(1997).
Albert, D., “The Effect of Cyclic-AMP on the Regulation of c-mycExpression in T Lymphoma Cells”, J. Clin. Invest., 95: 1490-1496(Apr., 1995).
Mednieks, et al., “Site-selective 8-C1-cAMP Which Causes Growth Inhibition and Differentiation Increases DNA (CRE)-binding Activity in Cancer Cells”, FEBS Lett., 254(1,2): 83-88(Aug. 1989).
Fentiman, et al., “Cyclic AMP Inhibits the Growth of Human Breast Cancer Cells in Defined Medium”, Mol. Biol. Med., 2: 81-88(1984).
Cassoni, et al., “Oxytocin Inhibits the Proliferation of MDA-MB231 Human Breast-Cancer Cells Via Cyclic Adenosine Monophosphate and Protein Kinase A”, Int. J. Cancer, 72: 340-344(1997).
Shafer, et al., “Reduces NDA Synthesis and Cell Viability in Small Cell Lung Carcinoma by Treatment with Cyclic AMP Phosphodiesterase Inhibitors”, Biochem. Pharmacol., 56: 1229-1236(1998).
Hoosein, et al., “Promotion of Differentiation in Human Colon Carcinoma Cells by Vasoactive Intestinal Polypeptide”, Regul. Peptides, 24: 15-26(1989).
Veber, et al., “Evidence for a Growth Effect of Epidermal Growth Factor on MDA-MB-231 Breast Cancer Cells”, Eur. J. Cancer, 30A(9): 1352-1359(1994).
Fontana, et al., “Inhibition of Human Mammary Carcinoma Cell Proliferation by Retinoids and Intracellular cAMP-Elevating Compounds”, J. Natl. Cancer Inst., 78(6): 1107-1112(Jun. 1987).
Slotkin, et al., “β-adrenoceptor Signaling and its Control of Cell Replication in MDA-MB-231 Human Breast Cancer Cells”, Breast Cancer Res. And Treatment, 60: 153-166(2000).
Singer, et al., “Cyclic Nucleotide Phosphodiesterases in Neoplastic and Nonneoplastic Human Mannary Tissues”, Cancer Res., 36: 60-66(Jan. 1976).
Soderling, et al., “Isolation and Characterization of a Dual-substrate Phosphodiesterase Gene Family:PDE10A”, Proc. Natl. Acad. Sci., 96: 7071-7076(Jun. 1999).
Loughney, et al., “Isolation and Characterization of PDE10A, a Novel Human 3′,5′-cyclic Nucleotide Phosphodiesterase”, Gene, 234: 109-117(1999).
Anderson, et al., “Synthesis and Murine Antineoplastic Activity of Bis[(carbamoyloxy)methyl] Derivatives of Pyrrolo[2,1-a]isoquinoline”, J. Med. Chem., 27: 1321-1325(1984).
Bauser Marcus
Boyer Stephen J.
Burkhardt Nils
Ergüden Jens-Kerim
Flubacher Dietmar
Bayer Pharmaceuticals Corporation
Huang Evelyn Mei
Pellegrino Susan M.
LandOfFree
Pyrrolo (2.1a)dihydroisoquinolines and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolo (2.1a)dihydroisoquinolines and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo (2.1a)dihydroisoquinolines and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3515742